Clausse Maria, Díaz Alejandra G, Ibañez Andrés E, Cassataro Juliana, Giambartolomei Guillermo H, Estein Silvia M
Laboratorio de Inmunología, Departamento SAMP, Facultad de Ciencias Veterinarias, Centro de Investigación Veterinaria de Tandil (CIVETAN-CONICET), Universidad Nacional del Centro de la Provincia de Buenos Aires, Tandil, Argentina.
Instituto de Inmunología, Genética y Metabolismo (CONICET/UBA), Buenos Aires, Argentina.
Clin Vaccine Immunol. 2014 Dec;21(12):1689-94. doi: 10.1128/CVI.00527-14. Epub 2014 Oct 22.
Canine brucellosis is an infectious disease caused by the Gram-negative bacterium Brucella canis. Unlike conventional control programs for other species of the genus Brucella, currently there is no vaccine available against canine brucellosis, and preventive measures are simply diagnosis and isolation of infected dogs. New approaches are therefore needed to develop an effective and safe immunization strategy against this zoonotic pathogen. In this study, BALB/c mice were subcutaneously immunized with the following: (i) the recombinant Brucella Omp31 antigen formulated in different adjuvants (incomplete Freund adjuvant, aluminum hydroxide, Quil A, and Montanide IMS 3012 VGPR), (ii) plasmid pCIOmp31, or (iii) pCIOmp31 plasmid followed by boosting with recombinant Omp31 (rOmp31). The immune response and the protective efficacy against B. canis infection were characterized. The different strategies induced a strong immunoglobulin G (IgG) response. Furthermore, spleen cells from rOmp31-immunized mice produced gamma interferon and interleukin-4 (IL-4) after in vitro stimulation with rOmp31, indicating the induction of a mixed Th1-Th2 response. Recombinant Omp31 administered with different adjuvants as well as the prime-boost strategy conferred protection against B. canis. In conclusion, our results suggest that Omp31 could be a useful candidate for the development of a subcellular vaccine against B. canis infection.
犬布鲁氏菌病是由革兰氏阴性菌犬布鲁氏菌引起的一种传染病。与针对布鲁氏菌属其他物种的传统防控方案不同，目前尚无针对犬布鲁氏菌病的疫苗，预防措施仅为对感染犬进行诊断和隔离。因此，需要新的方法来制定针对这种人畜共患病原体的有效且安全的免疫策略。在本研究中，将BALB/c小鼠皮下免疫以下物质：(i) 用不同佐剂（不完全弗氏佐剂、氢氧化铝、Quil A和Montanide IMS 3012 VGPR）配制的重组布鲁氏菌Omp31抗原，(ii) 质粒pCIOmp31，或(iii) pCIOmp31质粒，随后用重组Omp31（rOmp31）加强免疫。对免疫反应和针对犬布鲁氏菌感染的保护效力进行了表征。不同策略均诱导了强烈的免疫球蛋白G（IgG）反应。此外，rOmp31免疫小鼠的脾细胞在体外经rOmp31刺激后产生γ干扰素和白细胞介素-4（IL-4），表明诱导了混合的Th1-Th2反应。用不同佐剂给予的重组Omp31以及初免-加强策略均赋予了对犬布鲁氏菌的保护作用。总之，我们的结果表明，Omp31可能是开发针对犬布鲁氏菌感染的亚细胞疫苗的有用候选物。
